多基因谱在淋巴结阴性乳腺癌诊治中的应用

Multigene assay in diagnosis and treatment of node-negative breast cancer patients

根据美国国家综合癌症网或圣加仑共识原则的标准，有很多淋巴结阴性的乳腺癌患者接受了过治疗。多基因谱的研究提出可以通过对肿瘤基因信息的分析来判断患者的预后，从而更加准确地评价患者是否能得益于化疗。21、76、70、28基因谱的研究取得很大进展，目前研究最有应用前景的是21基因谱，2008年的美国国家综合癌症网指南推荐可以考虑一定适应证下的临床应用。

According to The National Comprehensive Cancer Network or St. Gallen criteria, many node-negative breast cancer patients are advised to receive chemotherapy, however, research has not demonstrated that chemotherapy benefits all of them equally. Muhigene assays, based on analysis about the genetic information of tumors, are likely to provide doctors with a better understanding of the aggressiveness of individual tumors, and a better assessment of a patient~ likely benefit from chemotherapy. Great progress has been made on the research of 21, 76, 70, 28 multigene assays. Among them, 21 gene assay is the most prospective, which has been recommended by The National Comprehensive Cancer Network in 2008 to use in the systemic adjuvant treatment decision in certain indications.